A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk.

The CYP19 gene codes for aromatase, a key steroidogenic enzyme involved in the conversion of androgens to estrogens. A tetranucleotide (TTTA) repeat polymorphism is present in intron 4 of CYP19; 2 out of 4 breast cancer case-control studies have reported a greater frequency of 2 specific alleles among affected women. We evaluated associations between CYP19 repeat alleles and breast cancer risk in a case-control study nested within the Nurses' Health Study cohort (incident cases: n=462; controls: n=618). We observed seven different CYP19 alleles (TTTA(7-13)). Compared to controls, cases had a statistically significant greater frequency of the 10 (TTTA)(10) repeat allele (10 allele: 2.3% vs. 0.7%, p = 0.005) and a nonsignificant increase in the frequency of the 12 (TTTA)(12) allele (12 allele: 3.1% vs. 2.1%, p = 0.11). A higher frequency of the 10 allele was observed in more advanced cancer cases defined as four or more involved nodes or distant metastasis [4+ nodes: 5/36 (13.9%) vs. 0-3 nodes: 13/330 (3.9%), p = 0.02]. Among controls, we found women with the 7 repeat allele to have decreased levels of estrone sulfate (-16.4%, p = 0.02), estrone (-6.1%, p = 0.22) and estradiol (-9.9%, p = 0.10), and a lower estrone/androstenedione ratio (E1/A) (-10.5%, p = 0.08) compared to non-carriers. A higher E1/A ratio and elevated estrogen levels were observed among carriers of the 8 repeat allele; E1/A ratio (+21.0%, p = 0.003), estrone (+7.5%, p = 0.16) and estradiol (+10.8%, p = 0.08). However, we observed no evidence of an association between these alleles and breast cancer risk. We were unable to make inferences regarding the effect of the 10 allele on hormone levels due to the small number of allele carriers in the subgroup with hormone levels. As this repeat polymorphism is not close to the splice sites in intron 4, linkage disequilibrium with other functional polymorphisms in CYP19 may explain the findings of an increased association between breast cancer and the 10 allele variant of CYP19. We did not detect any sequence variants in the regulatory region or in the adipose-specific exon I.4. The lack of an established effect on CYP19 function associated with the 10 allele means that these findings should be interpreted with caution.

[1]  B. Ponder,et al.  Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. , 2000, Carcinogenesis.

[2]  N. Probst-Hensch,et al.  Aromatase and breast cancer susceptibility. , 1999, Endocrine-related cancer.

[3]  W. Willett,et al.  The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. , 1999, Cancer research.

[4]  K. Buetow,et al.  Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk , 1999, British Journal of Cancer.

[5]  D. Clayton,et al.  Positive association of tyrosine hydroxylase microsatellite marker to essential hypertension. , 1998, Hypertension.

[6]  J. Manson,et al.  Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. , 1998, Journal of the National Cancer Institute.

[7]  Ji-ping Wang,et al.  In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. , 1998, Cancer research.

[8]  A. Børresen-Dale,et al.  A rare CYP19 (aromatase) variant may increase the risk of breast cancer. , 1998, Pharmacogenetics.

[9]  T. Nakayama,et al.  Association of a variable number of tandem repeats in the endothelial constitutive nitric oxide synthase gene with essential hypertension in Japanese. , 1998, American journal of hypertension.

[10]  O. Gotoh,et al.  Arginine-cysteine polymorphism at codon 264 of the human CYP19 gene does not affect aromatase activity. , 1997, Pharmacogenetics.

[11]  P. Jaeger,et al.  Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. , 1997, The Journal of clinical endocrinology and metabolism.

[12]  S. Bulun,et al.  Endocrine disorders associated with inappropriately high aromatase expression , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  P. V. van Helden,et al.  On simple repetitive DNA sequences and complex diseases , 1997, Electrophoresis.

[14]  N. Harada,et al.  Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. , 1996, The Journal of clinical endocrinology and metabolism.

[15]  J. Manson,et al.  Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  W. Miller,et al.  Analysis of the aromatase cytochrome P450 gene in human breast cancers. , 1994, Journal of molecular endocrinology.

[17]  N. Harada,et al.  Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. , 1994, Human pathology.

[18]  N. Harada,et al.  Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S L Zeger,et al.  Regression analysis for correlated data. , 1993, Annual review of public health.

[20]  A. Brodie.  Aromatase and its inhibitors—an overview , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  M. H. Polymeropoulos,et al.  Tetranucleotide repeat polymorphism at the human aromatase cytochrome P- 450 gene (CYP19) , 1991, Nucleic Acids Res..